Inhibitor Therapeutics (OTCMKTS:INTI) Posts Quarterly Earnings Results

Inhibitor Therapeutics (OTCMKTS:INTI) posted its earnings results on Friday. The company reported $999.00 EPS for the quarter, Zacks reports.

Inhibitor Therapeutics Stock Performance

Shares of Inhibitor Therapeutics stock remained flat at $0.08 on Friday. The stock had a trading volume of 15,477 shares, compared to its average volume of 8,522. Inhibitor Therapeutics has a 52 week low of $0.03 and a 52 week high of $0.12. The company has a fifty day moving average price of $0.09 and a 200 day moving average price of $0.07. The firm has a market capitalization of $14.35 million, a PE ratio of -8.30 and a beta of -0.58.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc and changed its name to Inhibitor Therapeutics, Inc in August 2019.